核心管线数据利空 基石药业股价大跌

21世纪经济报道
Jun 03

6月1日盘前,基石药业(2616.HK)宣布核心资产CS2009(PD-1/VEGF/CTLA-4三特异性抗体)的多项关键临床进展,于美国临床肿瘤学会(ASCO)年会上通过两份壁报正式发布,涵盖一线及后线非小细胞肺癌(NSCLC)及结直肠癌(CRC)患者I/II期临床试验数据,以及晚期实体瘤患者更长随访后的成熟I期临床数据。  公司首席执行官、研发总裁及执行董事杨建新博士表示,数据进一步确证了...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10